65,437 trials
Pain
Primary: To Characterize the Pharmacokinetic (PK) Profile of a Single Dose of Diclofenac Potassium Oral Solution, With Weight-based Dosing, in Pediatric Subjects, Ages 2-12 Years…
Plaque Psoriasis
Primary: Subjective Subject Preference Survey for the First Treatment Session — 81.1; 77.6 units on a scale
Epilepsy
Primary: The Change Scores in Memory Measures From Baseline to Post-treatment/Placebo Will be Compared Between the Memantine Treatment and Placebo Groups. — 1.00; 1.78; 4.38…
Cancer
Primary: Objective Response Rate (ORR) — 86 percentage of participants
Stroke · Cerebrovascular Accident · CVA
Primary: Fugl-Meyer Assessment of Upper Extremity Motor Impairment — 38.2; 39.8; 43.8; 41.0 units on a scale [0-66]
Bilateral Hearing Loss
Primary: Digit Span Total Raw Score (Construct Measured: Verbal Short-Term/Working Memory) — 11; 11.22; 12.89; 13 Scores on a scale — p=0.766
Lung Cancer
Primary: Progression-free Survival — 12.6 months
Tobacco Use Disorder
Primary: Craving — 5.17; 2.45; -1.05; -1.34 units on a scale
Lambert-Eaton Myasthenic Syndrome · Eaton-Lambert Myasthenic Syndrome
Primary: Number of Participants With 30% or More Deterioration in Triple Timed Up & Go (3TUG) Test, Compared to Time-matched Baseline — 0; 13 Participants — p=<0.0001
Cachexia · Non-Small Cell Lung Cancer
Primary: Percentage of Participants With Treatment-emergent Adverse Events — 52; 56 percentage of participants
Liver Neoplasms
Primary: Percent of Tumors With Increased Echogenicity (Brightness) Following Contrast-enhanced Sonography — 8 tumor
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities · Adult Acute Myeloid Leukemia With Del(5q) · Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Primary: Number of Patients With Dose Limiting Toxicity — 0; 4; 2; 2 Participants — p=0.03
Tear Film Characteristics
Primary: Tear Film Osmolarity — 293.4 mOsm/L
Menopause · Brain Activity · Cognition
Primary: Percent Change in Blood Oxygen Level Dependent (BOLD) Signal — 0.41; -0.11 percent change
Lung Cancer · Lung Tumor
Primary: Safety Endpoints — 22; 48; 25; 40 Events